Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.
You may also be interested in...
Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says
Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.
CMS Lacks Authority To Exempt Part B Drugs From Sequester Cuts – Tavenner
“We do not believe that we have the authority under the Budget Control Act of 2011 to exempt Medicare payment for Part B drugs,” CMS Administrator Marilyn Tavenner told members of Congress in a June 3 letter.
Sequester May Further Depress AmerisourceBergen’s Oncology Drug Sales
Wholesalers AmerisourceBergen and McKesson discuss the potential impact of the federal budget sequester and the resulting cut to Part B drug reimbursement on oncology drug sales.